--- title: "Chonluten: Dosing & Vendor Prices — BodyHackGuide" description: "Chonluten: dosing protocols, mechanism & side effects, 1 PubMed studies. Compare verified vendor prices." lang: en json-ld: | [ { "@context": "https://schema.org", "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "Home", "item": "https://www.bodyhackguide.co/" }, { "@type": "ListItem", "position": 2, "name": "Compounds", "item": "https://www.bodyhackguide.co/compare" }, { "@type": "ListItem", "position": 3, "name": "Chonluten" } ] }, { "@context": "https://schema.org", "@type": "MedicalWebPage", "name": "Chonluten", "description": "Chonluten is a bioregulator preparation originating from Vladimir Khavinson's St. Petersburg Institute of Bioregulation and Gerontology, positioned as a \"bronchial bioregulator\" intended to support respiratory epithelium, alveolar function, and airway regeneration in chronic obstructive pulmonary disease (COPD), chronic bronchitis, post-infectious respiratory dysfunction, and age-related decline of pulmonary function. Historically Chonluten has been marketed in two overlapping forms: (1) as a polypeptide extract prepared from bovine or porcine bronchial mucosa — an undefined-mixture \"natural bioregulator\" — and (2) as a defined-sequence synthetic short peptide, most commonly cited as the tripeptide Glu-Asp-Gly (EDG) in later Khavinson publications, sometimes rendered H-Glu-Asp-Gly-OH or E-D-G. Chonluten is closely related to Bronchogen, which Khavinson's group developed as the longer tetrapeptide (Ala-Glu-Asp-Pro / AEDP) synthetic alternative in the same respiratory-bioregulator class, and sits alongside Pinealon, Thymogen, Vilon, Epitalon, Livagen, Cardiogen, and Cartalax within the broader Khavinson peptide-bioregulator programme. Outside Russia and a small number of former-Soviet-state publications, Chonluten is not a registered pharmaceutical, not FDA- or EMA-reviewed, not listed in WADA categories, and does not appear in GOLD, ATS/ERS, or NICE guidelines for COPD or chronic bronchitis. Published Russian work — most of it authored by Khavinson and collaborators — comprises in vitro studies in bronchial epithelial cell culture, rodent lung injury experiments, and small uncontrolled observational case series in elderly COPD and chronic bronchitis patients ([Khavinson et al., 2011]; [Chalisova et al., 2015]; [Anisimov et al., 2010]). The relationship between Chonluten and Bronchogen deserves clear description. Both are positioned as respiratory bioregulators within the Khavinson framework. Chonluten in polypeptide-extract form was the original bronchial bioregulator — an undefined mixture from animal tissue, prepared by the extraction methodology Khavinson developed in the 1970s and 1980s. Bronchogen (AEDP) was subsequently synthesised as a defined tetrapeptide intended to reproduce the extract's biological activity in chemically characterised form. Chonluten in short-peptide form (EDG) represents a further minimisation to three amino acids, testing whether an even shorter sequence retains bioregulator activity. All three products — Chonluten extract, Chonluten-EDG, and Bronchogen-AEDP — are sold in the post-Soviet supplement market with overlapping positioning. BodyHackGuide covers Chonluten because it is sold online as both oral capsule (typically 20 mg with undisclosed active content) and injectable forms, and because it appears in longevity-stack discussions as a respiratory-support bioregulator. We describe what is known, what is claimed, and what is missing — and we steer readers seeking evidence-graded respiratory support toward the interventions with substantial replication: smoking cessation (by far the single highest-impact intervention), pulmonary rehabilitation, inhaled short- and long-acting bronchodilators for obstructive disease, inhaled corticosteroids where indicated, vaccinations (influenza, pneumococcal, COVID-19, RSV in older adults), weight management for restrictive/obesity-related disease, and specific biologic therapy (benralizumab, mepolizumab, dupilumab, tezepelumab) for severe asthma phenotypes. Chonluten is a plausible hypothesis within the Khavinson framework. It is not, in 2026, an evidence-graded respiratory therapy.", "lastReviewed": "2026-05-04T11:34:06.208+00:00", "url": "https://www.bodyhackguide.co/compound/chonluten", "author": { "@type": "Person", "name": "BioChonch", "url": "https://www.bodyhackguide.co/about", "jobTitle": "Founder & Lead Researcher", "sameAs": [ "https://x.com/bodyhackguide", "https://reddit.com/r/BodyHackGuide", "https://reddit.com/r/BrainHackGuide", "https://reddit.com/r/Biohackingher" ], "worksFor": { "@type": "Organization", "name": "BodyHackGuide", "url": "https://www.bodyhackguide.co" } }, "reviewedBy": { "@type": "Person", "name": "BioChonch", "url": "https://www.bodyhackguide.co/about", "jobTitle": "Founder & Lead Researcher", "sameAs": [ "https://x.com/bodyhackguide", "https://reddit.com/r/BodyHackGuide", "https://reddit.com/r/BrainHackGuide", "https://reddit.com/r/Biohackingher" ], "worksFor": { "@type": "Organization", "name": "BodyHackGuide", "url": "https://www.bodyhackguide.co" } }, "publisher": { "@type": "Organization", "name": "BodyHackGuide", "url": "https://www.bodyhackguide.co" }, "mainContentOfPage": { "@type": "WebPageElement", "cssSelector": "main" }, "about": { "@type": "Drug", "name": "Chonluten", "alternateName": [ "Pulmonary peptide" ], "description": "Chonluten is a bioregulator preparation originating from Vladimir Khavinson's St. Petersburg Institute of Bioregulation and Gerontology, positioned as a \"bronchial bioregulator\" intended to support respiratory epithelium, alveolar function, and airway regeneration in chronic obstructive pulmonary disease (COPD), chronic bronchitis, post-infectious respiratory dysfunction, and age-related decline of pulmonary function. Historically Chonluten has been marketed in two overlapping forms: (1) as a polypeptide extract prepared from bovine or porcine bronchial mucosa — an undefined-mixture \"natural bioregulator\" — and (2) as a defined-sequence synthetic short peptide, most commonly cited as the tripeptide Glu-Asp-Gly (EDG) in later Khavinson publications, sometimes rendered H-Glu-Asp-Gly-OH or E-D-G. Chonluten is closely related to Bronchogen, which Khavinson's group developed as the longer tetrapeptide (Ala-Glu-Asp-Pro / AEDP) synthetic alternative in the same respiratory-bioregulator class, and sits alongside Pinealon, Thymogen, Vilon, Epitalon, Livagen, Cardiogen, and Cartalax within the broader Khavinson peptide-bioregulator programme. Outside Russia and a small number of former-Soviet-state publications, Chonluten is not a registered pharmaceutical, not FDA- or EMA-reviewed, not listed in WADA categories, and does not appear in GOLD, ATS/ERS, or NICE guidelines for COPD or chronic bronchitis. Published Russian work — most of it authored by Khavinson and collaborators — comprises in vitro studies in bronchial epithelial cell culture, rodent lung injury experiments, and small uncontrolled observational case series in elderly COPD and chronic bronchitis patients ([Khavinson et al., 2011]; [Chalisova et al., 2015]; [Anisimov et al., 2010]). The relationship between Chonluten and Bronchogen deserves clear description. Both are positioned as respiratory bioregulators within the Khavinson framework. Chonluten in polypeptide-extract form was the original bronchial bioregulator — an undefined mixture from animal tissue, prepared by the extraction methodology Khavinson developed in the 1970s and 1980s. Bronchogen (AEDP) was subsequently synthesised as a defined tetrapeptide intended to reproduce the extract's biological activity in chemically characterised form. Chonluten in short-peptide form (EDG) represents a further minimisation to three amino acids, testing whether an even shorter sequence retains bioregulator activity. All three products — Chonluten extract, Chonluten-EDG, and Bronchogen-AEDP — are sold in the post-Soviet supplement market with overlapping positioning. BodyHackGuide covers Chonluten because it is sold online as both oral capsule (typically 20 mg with undisclosed active content) and injectable forms, and because it appears in longevity-stack discussions as a respiratory-support bioregulator. We describe what is known, what is claimed, and what is missing — and we steer readers seeking evidence-graded respiratory support toward the interventions with substantial replication: smoking cessation (by far the single highest-impact intervention), pulmonary rehabilitation, inhaled short- and long-acting bronchodilators for obstructive disease, inhaled corticosteroids where indicated, vaccinations (influenza, pneumococcal, COVID-19, RSV in older adults), weight management for restrictive/obesity-related disease, and specific biologic therapy (benralizumab, mepolizumab, dupilumab, tezepelumab) for severe asthma phenotypes. Chonluten is a plausible hypothesis within the Khavinson framework. It is not, in 2026, an evidence-graded respiratory therapy.", "activeIngredient": "Chonluten", "mechanismOfAction": "Mechanism of Action Chonluten's proposed mechanism differs depending on which form is under discussion, but all three variants (polypeptide extract, synthetic EDG tripeptide, and by extension the related AEDL tetrapeptide Bronchogen) fall within the Khavinson short-peptide bioregulator framework. Polypeptide extract form (historical Chonluten) The bovine/porcine bronchial polypeptide extract is an undefined mixture of low-molecular-weight peptides prepared by aqueous extraction of bronchial mucosa followed by ultrafiltration or gel filtration. Molecular weight range is typically reported as 1,000-10,000 daltons. The proposed mechanism is tissue-derived bioregulator signalling - that animal-tissue-derived peptide mixtures retain tissue-specific regulatory information that can guide homologous tissue regeneration in recipient organisms. This framework is mechanistically vague by modern pharmacology standards. It predates the era in which individual bioactive components can be identified and characterised. Chonluten extract cannot be described with molecular specificity because its composition is not defined. Synthetic EDG tripeptide (later Chonluten formulation) At approximately 319 daltons (H-Glu-Asp-Gly-OH), the synthetic tripeptide is small enough to cross membranes passively. The Khavinson framework proposes that EDG enters bronchial epithelial cells, diffuses into nuclei, and makes sequence-selective contacts with exposed DNA regions and histone tails, producing preferential upregulation of respiratory-epithelial survival and regeneration programmes - ciliogenesis, mucin transcription, surfactant production, anti-inflammatory programmes. Three mechanistic layers in the Khavinson framework: Passive membrane permeation. EDG is sufficiently small and polar to cross phospholipid bilayers. Tritiated-peptide biodistribution in rodents reports lung uptake after intraperitoneal or oral administration, with radiolabel recovered in multiple tissues. Intact-peptide versus catabolite distinction is not made in the available data. Nuclear import. Passive diffusion through nuclear pores is assumed. No karyopherin-mediated import is invoked. At 319 daltons, nuclear pore passage is plausible. Chromatin modulation. Sequence-selective contacts with DNA and histone tails produce tissue-appropriate gene expression changes. This is the framework-level claim; it is not validated by modern chromatin biology methods (ChIP-seq, ATAC-seq, CUT&RUN) in any Khavinson peptide. Relation to Bronchogen (AEDL) Bronchogen is the closely-related tetrapeptide (Ala-Glu-Asp-Leu, AEDL) in the same respiratory-bioregulator class. (Note: the Ala-Glu-Asp-Pro / AEDP sequence is Cortagen, a different Khavinson peptide - not Bronchogen.) Khavinson positions EDG Chonluten and AEDL Bronchogen as related but distinct sequences with possibly different preferred chromatin targets. In differential scanning calorimetry, Bronchogen behaved as a non-sequence-specific DNA-stabilising ligand that raised the DNA melting temperature (Monaselidze & Khavinson, 2011); comparable calorimetric data specific to EDG Chonluten are not available, so the claim of differential chromatin targeting between the two remains unproven. Alternative conservative framing A parsimonious interpretation treats Chonluten EDG as a glutamate-aspartate-glycine tripeptide delivering three amino acids in rapidly-absorbed short-peptide form. Biological effects could reflect substrate delivery, non-specific amino-acid signalling (glutamate as an excitatory signal, glycine as an inhibitory neurotransmitter and glutathione precursor), or non-specific nutritional support to stressed respiratory tissue. Under this framing, any equivalent amino-acid delivery would produce similar effects. Polypeptide extract alternative framing The polypeptide extract form contains unknown bioactive components. Any mechanistic claim about the extract must acknowledge that (a) individual active components are not isolated or characterised, (b) batch-to-batch variation is uncontrolled, and (c) modern pharmacology requires defined composition for mechanism attribution. The extract might contain biologically active peptides; it might also contain predominantly inert material with minimal bioactivity. Without defined composition, the mechanistic claim is untestable. Receptor pharmacology No GPCR, nuclear receptor, or defined enzyme target identified for Chonluten in either form. It does not engage -adrenoceptors (bronchodilator targets), muscarinic receptors (anticholinergic bronchodilator targets), glucocorticoid receptors (inhaled corticosteroid targets), or known inflammatory signalling nodes (IL-5, IL-13, TSLP - biologic therapy targets). The absence of a defined pharmacological target is characteristic of the Khavinson bioregulator class. Compared to evidence-graded respiratory pharmacology Inhaled 2-agonists cause bronchodilation via structurally characterised receptor activation with minute-level kinetics. Inhaled corticosteroids suppress eosinophilic inflammation via glucocorticoid receptor activation with decades of RCT validation. Long-acting muscarinic antagonists block parasympathetic bronchoconstriction with mapped receptor kinetics. Biologics block specific cytokines (IL-5, IL-4/13, TSLP) with validated mechanism and registered indications. Chonluten sits at a completely different mechanism-specification level - framework-level hypothesis rather than measured pharmacology.", "legalStatus": "Not approved for human use — research chemical", "warning": "For research purposes only. Not for human consumption." } }, { "@context": "https://schema.org", "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "What is Chonluten and what is it claimed to do?", "acceptedAnswer": { "@type": "Answer", "text": "Chonluten is a respiratory bioregulator from Vladimir Khavinson's St. Petersburg Institute, marketed in two overlapping forms: (1) a polypeptide extract prepared from bovine or porcine bronchial mucosa, and (2) a defined-sequence synthetic short peptide, most commonly Glu-Asp-Gly (EDG). It is positioned as support for bronchial epithelium, alveolar function, and airway regeneration in COPD, chronic bronchitis, and post-infectious respiratory dysfunction. Russian-language literature reports in vitro bronchial epithelial effects and small uncontrolled observational series in elderly respiratory patients; these reports are largely not PubMed-indexed and have not been independently replicated in the West. Not FDA/EMA-approved, not in any respiratory guideline. Treat as experimental." } }, { "@type": "Question", "name": "How is Chonluten different from Bronchogen?", "acceptedAnswer": { "@type": "Answer", "text": "Both are respiratory bioregulators in the Khavinson framework. Chonluten was the original - either a bovine/porcine bronchial polypeptide extract or the synthetic Glu-Asp-Gly tripeptide. Bronchogen is the tetrapeptide Ala-Glu-Asp-Leu (AEDL) synthesised as a defined-sequence alternative in the same respiratory bioregulator class (note: the Ala-Glu-Asp-Pro / AEDP sequence is Cortagen, a different Khavinson peptide, not Bronchogen). Bronchogen has slightly more in vitro and rodent data; the one Bronchogen paper indexed in PubMed is a differential-scanning-calorimetry study showing it stabilises DNA (Monaselidze & Khavinson, 2011). Community users sometimes stack both or alternate between them; there is no head-to-head evidence establishing which is superior. If budget-constrained, pick one rather than running both simultaneously." } }, { "@type": "Question", "name": "Does Chonluten actually help with COPD or chronic bronchitis?", "acceptedAnswer": { "@type": "Answer", "text": "Honest answer: the evidence is thin. Russian uncontrolled observational series report subjective improvement and modest spirometry changes after 20-30 day oral cycles. No placebo-controlled RCTs exist. No head-to-head comparison with inhaled bronchodilators, ICS, or biologics. For COPD and chronic bronchitis, evidence-graded first-line is smoking cessation, inhaled bronchodilators, ICS where indicated, pulmonary rehabilitation, vaccinations, and specific biologic therapy for severe asthma phenotypes. Chonluten is a speculative adjunct, not a substitute." } }, { "@type": "Question", "name": "What is the correct Chonluten dose?", "acceptedAnswer": { "@type": "Answer", "text": "Khavinson convention: 20 mg oral/sublingual capsule once daily for 10 consecutive days, 60-90 day washouts. 20 mg capsule contains undisclosed actual active content (historically 2-4 mg peptide or peptide-fraction for extract forms). For synthetic EDG subcutaneous, 2-5 mg daily for 10 days. Autumn entry before winter respiratory season is Russian clinical convention. No dose-ranging trial has established that 20 mg is optimal." } }, { "@type": "Question", "name": "Is Chonluten safe?", "acceptedAnswer": { "@type": "Answer", "text": "Short-term safety signal from Russian literature is mild - occasional nausea, mild headache, rare rash. Extract form has slightly higher allergic reaction rate, likely reflecting bovine/porcine protein recognition. Animal protein allergy is a contraindication for extract form. Pregnancy, breastfeeding, paediatric use, active lung cancer, active TB, and acute respiratory infections are absolute contraindications. Use third-party verified product. For extract form, ensure pathogen screening and sourcing documentation." } }, { "@type": "Question", "name": "Should I use Chonluten extract or synthetic EDG tripeptide?", "acceptedAnswer": { "@type": "Answer", "text": "The synthetic EDG tripeptide is the cleaner choice - chemically defined, no animal protein, lower allergic-reaction risk, no prion-disease concern. The polypeptide extract is the historical form and some users prefer it based on the argument that the undefined mixture contains bioactivity not captured by the minimised synthetic sequence. This argument is theoretical. For users with any animal-protein allergy, the synthetic EDG form is clearly preferable. For users prioritising modern pharmaceutical quality standards, the synthetic form is preferable. The extract form has historical precedent but fewer modern quality advantages." } }, { "@type": "Question", "name": "Can I use Chonluten with inhaled bronchodilators or corticosteroids?", "acceptedAnswer": { "@type": "Answer", "text": "Yes, from an interaction standpoint. No documented pharmacokinetic or pharmacodynamic interactions between Chonluten and inhaled 2-agonists, muscarinic antagonists, or corticosteroids. The inhaled drugs act locally with minimal systemic exposure. Continue inhaled maintenance therapy during Chonluten cycles - do not substitute Chonluten for inhalers. Notify your pulmonologist of bioregulator cycles." } }, { "@type": "Question", "name": "How does Chonluten compare to other Khavinson peptides?", "acceptedAnswer": { "@type": "Answer", "text": "Chonluten is one of two Khavinson respiratory bioregulators - the other being Bronchogen (AEDL tetrapeptide). Chonluten historically preceded Bronchogen as the bovine-bronchial extract, and Glu-Asp-Gly emerged as a proposed defined-sequence active component. Within the broader Khavinson family (Epitalon, Pinealon, Thymogen, Vilon, Livagen, Cardiogen, Cartalax), Chonluten occupies the respiratory niche alongside Bronchogen. Evidence base is smaller than for Epitalon (most-studied) or Thymogen (most regulatory recognition)." } }, { "@type": "Question", "name": "Where do I source quality Chonluten?", "acceptedAnswer": { "@type": "Answer", "text": "Supply channels: post-Soviet supplement vendors (20 mg oral capsules, both extract and synthetic forms available), and international research-peptide suppliers (lyophilised synthetic EDG). For extract form, require pathogen screening documentation and bovine/porcine source transparency. For synthetic form, require third-party HPLC peptide content confirmation and endotoxin testing. Avoid vendors without certificates of analysis. Higher verified-quality product is worth the cost premium - this is particularly true for the extract form given animal-tissue origin." } }, { "@type": "Question", "name": "If I have respiratory issues and see a BodyHackGuide ad, what is the actual priority list?", "acceptedAnswer": { "@type": "Answer", "text": "For respiratory health through BodyHackGuide ad funnel, evidence-graded ranked: (1) smoking cessation if applicable - nothing else matters nearly as much; (2) pulmonary rehabilitation and structured exercise; (3) vaccinations (influenza, pneumococcal, COVID-19, RSV); (4) clinician-prescribed inhaled therapy for obstructive disease; (5) NAC 600-1200 mg daily for chronic bronchitis; (6) environmental air quality and allergen reduction; (7) evidence-based biologics for severe asthma phenotypes; (8) weight management for obesity-related disease; (9) experimental bioregulators like Chonluten, Bronchogen as advanced-protocol tier-9 add-ons. Use ads to capture respiratory-interested traffic, convert to evidence-graded content, offer Chonluten only to users who have exhausted proven options." } } ] }, { "@context": "https://schema.org", "@type": "Organization", "@id": "https://www.bodyhackguide.co#organization", "name": "BodyHackGuide", "alternateName": "BHG", "url": "https://www.bodyhackguide.co", "logo": { "@type": "ImageObject", "url": "https://www.bodyhackguide.co/logo.png", "width": 512, "height": 512 }, "description": "Evidence-based research reference for peptides and nootropics. 124+ compound profiles, interactive dosing calculators, real-time vendor pricing, and trust-scored vendor reviews scored on a public, reproducible methodology applied to every vendor. BodyHackGuide and BHG Labs share common ownership, and we earn a commission on purchases through our links.", "foundingDate": "2024", "founder": { "@id": "https://www.bodyhackguide.co/about#person" }, "sameAs": [ "https://x.com/bodyhackguide", "https://reddit.com/r/BodyHackGuide", "https://reddit.com/r/BrainHackGuide", "https://reddit.com/r/Biohackingher", "https://discord.gg/Mhq5UdRYBA" ], "knowsAbout": [ "Peptide research", "Nootropic research", "Biohacking", "Compound dosing", "Vendor transparency" ], "publishingPrinciples": "https://www.bodyhackguide.co/editorial-standards", "ethicsPolicy": "https://www.bodyhackguide.co/editorial-standards", "diversityPolicy": "https://www.bodyhackguide.co/editorial-standards" }, { "@context": "https://schema.org", "@type": "MedicalWebPage", "name": "Chonluten", "description": "Chonluten is a bioregulator preparation originating from Vladimir Khavinson's St. Petersburg Institute of Bioregulation and Gerontology, positioned as a \"bronchial bioregulator\" intended to support respiratory epithelium, alveolar function, and airway regeneration in chronic obstructive pulmonary disease (COPD), chronic bronchitis, post-infectious respiratory dysfunction, and age-related decline of pulmonary function. Historically Chonluten has been marketed in two overlapping forms: (1) as a polypeptide extract prepared from bovine or porcine bronchial mucosa — an undefined-mixture \"natural bioregulator\" — and (2) as a defined-sequence synthetic short peptide, most commonly cited as the tripeptide Glu-Asp-Gly (EDG) in later Khavinson publications, sometimes rendered H-Glu-Asp-Gly-OH or E-D-G. Chonluten is closely related to Bronchogen, which Khavinson's group developed as the longer tetrapeptide (Ala-Glu-Asp-Pro / AEDP) synthetic alternative in the same respiratory-bioregulator class, and sits alongside Pinealon, Thymogen, Vilon, Epitalon, Livagen, Cardiogen, and Cartalax within the broader Khavinson peptide-bioregulator programme. Outside Russia and a small number of former-Soviet-state publications, Chonluten is not a registered pharmaceutical, not FDA- or EMA-reviewed, not listed in WADA categories, and does not appear in GOLD, ATS/ERS, or NICE guidelines for COPD or chronic bronchitis. Published Russian work — most of it authored by Khavinson and collaborators — comprises in vitro studies in bronchial epithelial cell culture, rodent lung injury experiments, and small uncontrolled observational case series in elderly COPD and chronic bronchitis patients ([Khavinson et al., 2011]; [Chalisova et al., 2015]; [Anisimov et al., 2010]). The relationship between Chonluten and Bronchogen deserves clear description. Both are positioned as respiratory bioregulators within the Khavinson framework. Chonluten in polypeptide-extract form was the original bronchial bioregulator — an undefined mixture from animal tissue, prepared by the extraction methodology Khavinson developed in the 1970s and 1980s. Bronchogen (AEDP) was subsequently synthesised as a defined tetrapeptide intended to reproduce the extract's biological activity in chemically characterised form. Chonluten in short-peptide form (EDG) represents a further minimisation to three amino acids, testing whether an even shorter sequence retains bioregulator activity. All three products — Chonluten extract, Chonluten-EDG, and Bronchogen-AEDP — are sold in the post-Soviet supplement market with overlapping positioning. BodyHackGuide covers Chonluten because it is sold online as both oral capsule (typically 20 mg with undisclosed active content) and injectable forms, and because it appears in longevity-stack discussions as a respiratory-support bioregulator. We describe what is known, what is claimed, and what is missing — and we steer readers seeking evidence-graded respiratory support toward the interventions with substantial replication: smoking cessation (by far the single highest-impact intervention), pulmonary rehabilitation, inhaled short- and long-acting bronchodilators for obstructive disease, inhaled corticosteroids where indicated, vaccinations (influenza, pneumococcal, COVID-19, RSV in older adults), weight management for restrictive/obesity-related disease, and specific biologic therapy (benralizumab, mepolizumab, dupilumab, tezepelumab) for severe asthma phenotypes. Chonluten is a plausible hypothesis within the Khavinson framework. It is not, in 2026, an evidence-graded respiratory therapy.", "lastReviewed": "2026-05-04T11:34:06.208+00:00", "url": "https://www.bodyhackguide.co/compound/chonluten", "author": { "@type": "Person", "name": "BioChonch", "url": "https://www.bodyhackguide.co/about", "jobTitle": "Founder & Lead Researcher", "sameAs": [ "https://x.com/bodyhackguide", "https://reddit.com/r/BodyHackGuide", "https://reddit.com/r/BrainHackGuide", "https://reddit.com/r/Biohackingher" ], "worksFor": { "@type": "Organization", "name": "BodyHackGuide", "url": "https://www.bodyhackguide.co" } }, "reviewedBy": { "@type": "Person", "name": "BioChonch", "url": "https://www.bodyhackguide.co/about", "jobTitle": "Founder & Lead Researcher", "sameAs": [ "https://x.com/bodyhackguide", "https://reddit.com/r/BodyHackGuide", "https://reddit.com/r/BrainHackGuide", "https://reddit.com/r/Biohackingher" ], "worksFor": { "@type": "Organization", "name": "BodyHackGuide", "url": "https://www.bodyhackguide.co" } }, "publisher": { "@type": "Organization", "name": "BodyHackGuide", "url": "https://www.bodyhackguide.co" }, "mainContentOfPage": { "@type": "WebPageElement", "cssSelector": "main" }, "about": { "@type": "Drug", "name": "Chonluten", "alternateName": [ "Pulmonary peptide" ], "description": "Chonluten is a bioregulator preparation originating from Vladimir Khavinson's St. Petersburg Institute of Bioregulation and Gerontology, positioned as a \"bronchial bioregulator\" intended to support respiratory epithelium, alveolar function, and airway regeneration in chronic obstructive pulmonary disease (COPD), chronic bronchitis, post-infectious respiratory dysfunction, and age-related decline of pulmonary function. Historically Chonluten has been marketed in two overlapping forms: (1) as a polypeptide extract prepared from bovine or porcine bronchial mucosa — an undefined-mixture \"natural bioregulator\" — and (2) as a defined-sequence synthetic short peptide, most commonly cited as the tripeptide Glu-Asp-Gly (EDG) in later Khavinson publications, sometimes rendered H-Glu-Asp-Gly-OH or E-D-G. Chonluten is closely related to Bronchogen, which Khavinson's group developed as the longer tetrapeptide (Ala-Glu-Asp-Pro / AEDP) synthetic alternative in the same respiratory-bioregulator class, and sits alongside Pinealon, Thymogen, Vilon, Epitalon, Livagen, Cardiogen, and Cartalax within the broader Khavinson peptide-bioregulator programme. Outside Russia and a small number of former-Soviet-state publications, Chonluten is not a registered pharmaceutical, not FDA- or EMA-reviewed, not listed in WADA categories, and does not appear in GOLD, ATS/ERS, or NICE guidelines for COPD or chronic bronchitis. Published Russian work — most of it authored by Khavinson and collaborators — comprises in vitro studies in bronchial epithelial cell culture, rodent lung injury experiments, and small uncontrolled observational case series in elderly COPD and chronic bronchitis patients ([Khavinson et al., 2011]; [Chalisova et al., 2015]; [Anisimov et al., 2010]). The relationship between Chonluten and Bronchogen deserves clear description. Both are positioned as respiratory bioregulators within the Khavinson framework. Chonluten in polypeptide-extract form was the original bronchial bioregulator — an undefined mixture from animal tissue, prepared by the extraction methodology Khavinson developed in the 1970s and 1980s. Bronchogen (AEDP) was subsequently synthesised as a defined tetrapeptide intended to reproduce the extract's biological activity in chemically characterised form. Chonluten in short-peptide form (EDG) represents a further minimisation to three amino acids, testing whether an even shorter sequence retains bioregulator activity. All three products — Chonluten extract, Chonluten-EDG, and Bronchogen-AEDP — are sold in the post-Soviet supplement market with overlapping positioning. BodyHackGuide covers Chonluten because it is sold online as both oral capsule (typically 20 mg with undisclosed active content) and injectable forms, and because it appears in longevity-stack discussions as a respiratory-support bioregulator. We describe what is known, what is claimed, and what is missing — and we steer readers seeking evidence-graded respiratory support toward the interventions with substantial replication: smoking cessation (by far the single highest-impact intervention), pulmonary rehabilitation, inhaled short- and long-acting bronchodilators for obstructive disease, inhaled corticosteroids where indicated, vaccinations (influenza, pneumococcal, COVID-19, RSV in older adults), weight management for restrictive/obesity-related disease, and specific biologic therapy (benralizumab, mepolizumab, dupilumab, tezepelumab) for severe asthma phenotypes. Chonluten is a plausible hypothesis within the Khavinson framework. It is not, in 2026, an evidence-graded respiratory therapy.", "activeIngredient": "Chonluten", "mechanismOfAction": "Mechanism of Action Chonluten's proposed mechanism differs depending on which form is under discussion, but all three variants (polypeptide extract, synthetic EDG tripeptide, and by extension the related AEDL tetrapeptide Bronchogen) fall within the Khavinson short-peptide bioregulator framework. Polypeptide extract form (historical Chonluten) The bovine/porcine bronchial polypeptide extract is an undefined mixture of low-molecular-weight peptides prepared by aqueous extraction of bronchial mucosa followed by ultrafiltration or gel filtration. Molecular weight range is typically reported as 1,000-10,000 daltons. The proposed mechanism is tissue-derived bioregulator signalling - that animal-tissue-derived peptide mixtures retain tissue-specific regulatory information that can guide homologous tissue regeneration in recipient organisms. This framework is mechanistically vague by modern pharmacology standards. It predates the era in which individual bioactive components can be identified and characterised. Chonluten extract cannot be described with molecular specificity because its composition is not defined. Synthetic EDG tripeptide (later Chonluten formulation) At approximately 319 daltons (H-Glu-Asp-Gly-OH), the synthetic tripeptide is small enough to cross membranes passively. The Khavinson framework proposes that EDG enters bronchial epithelial cells, diffuses into nuclei, and makes sequence-selective contacts with exposed DNA regions and histone tails, producing preferential upregulation of respiratory-epithelial survival and regeneration programmes - ciliogenesis, mucin transcription, surfactant production, anti-inflammatory programmes. Three mechanistic layers in the Khavinson framework: Passive membrane permeation. EDG is sufficiently small and polar to cross phospholipid bilayers. Tritiated-peptide biodistribution in rodents reports lung uptake after intraperitoneal or oral administration, with radiolabel recovered in multiple tissues. Intact-peptide versus catabolite distinction is not made in the available data. Nuclear import. Passive diffusion through nuclear pores is assumed. No karyopherin-mediated import is invoked. At 319 daltons, nuclear pore passage is plausible. Chromatin modulation. Sequence-selective contacts with DNA and histone tails produce tissue-appropriate gene expression changes. This is the framework-level claim; it is not validated by modern chromatin biology methods (ChIP-seq, ATAC-seq, CUT&RUN) in any Khavinson peptide. Relation to Bronchogen (AEDL) Bronchogen is the closely-related tetrapeptide (Ala-Glu-Asp-Leu, AEDL) in the same respiratory-bioregulator class. (Note: the Ala-Glu-Asp-Pro / AEDP sequence is Cortagen, a different Khavinson peptide - not Bronchogen.) Khavinson positions EDG Chonluten and AEDL Bronchogen as related but distinct sequences with possibly different preferred chromatin targets. In differential scanning calorimetry, Bronchogen behaved as a non-sequence-specific DNA-stabilising ligand that raised the DNA melting temperature (Monaselidze & Khavinson, 2011); comparable calorimetric data specific to EDG Chonluten are not available, so the claim of differential chromatin targeting between the two remains unproven. Alternative conservative framing A parsimonious interpretation treats Chonluten EDG as a glutamate-aspartate-glycine tripeptide delivering three amino acids in rapidly-absorbed short-peptide form. Biological effects could reflect substrate delivery, non-specific amino-acid signalling (glutamate as an excitatory signal, glycine as an inhibitory neurotransmitter and glutathione precursor), or non-specific nutritional support to stressed respiratory tissue. Under this framing, any equivalent amino-acid delivery would produce similar effects. Polypeptide extract alternative framing The polypeptide extract form contains unknown bioactive components. Any mechanistic claim about the extract must acknowledge that (a) individual active components are not isolated or characterised, (b) batch-to-batch variation is uncontrolled, and (c) modern pharmacology requires defined composition for mechanism attribution. The extract might contain biologically active peptides; it might also contain predominantly inert material with minimal bioactivity. Without defined composition, the mechanistic claim is untestable. Receptor pharmacology No GPCR, nuclear receptor, or defined enzyme target identified for Chonluten in either form. It does not engage -adrenoceptors (bronchodilator targets), muscarinic receptors (anticholinergic bronchodilator targets), glucocorticoid receptors (inhaled corticosteroid targets), or known inflammatory signalling nodes (IL-5, IL-13, TSLP - biologic therapy targets). The absence of a defined pharmacological target is characteristic of the Khavinson bioregulator class. Compared to evidence-graded respiratory pharmacology Inhaled 2-agonists cause bronchodilation via structurally characterised receptor activation with minute-level kinetics. Inhaled corticosteroids suppress eosinophilic inflammation via glucocorticoid receptor activation with decades of RCT validation. Long-acting muscarinic antagonists block parasympathetic bronchoconstriction with mapped receptor kinetics. Biologics block specific cytokines (IL-5, IL-4/13, TSLP) with validated mechanism and registered indications. Chonluten sits at a completely different mechanism-specification level - framework-level hypothesis rather than measured pharmacology.", "legalStatus": "Not approved for human use — research chemical", "warning": "For research purposes only. Not for human consumption." } }, { "@context": "https://schema.org", "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "What is Chonluten and what is it claimed to do?", "acceptedAnswer": { "@type": "Answer", "text": "Chonluten is a respiratory bioregulator from Vladimir Khavinson's St. Petersburg Institute, marketed in two overlapping forms: (1) a polypeptide extract prepared from bovine or porcine bronchial mucosa, and (2) a defined-sequence synthetic short peptide, most commonly Glu-Asp-Gly (EDG). It is positioned as support for bronchial epithelium, alveolar function, and airway regeneration in COPD, chronic bronchitis, and post-infectious respiratory dysfunction. Russian-language literature reports in vitro bronchial epithelial effects and small uncontrolled observational series in elderly respiratory patients; these reports are largely not PubMed-indexed and have not been independently replicated in the West. Not FDA/EMA-approved, not in any respiratory guideline. Treat as experimental." } }, { "@type": "Question", "name": "How is Chonluten different from Bronchogen?", "acceptedAnswer": { "@type": "Answer", "text": "Both are respiratory bioregulators in the Khavinson framework. Chonluten was the original - either a bovine/porcine bronchial polypeptide extract or the synthetic Glu-Asp-Gly tripeptide. Bronchogen is the tetrapeptide Ala-Glu-Asp-Leu (AEDL) synthesised as a defined-sequence alternative in the same respiratory bioregulator class (note: the Ala-Glu-Asp-Pro / AEDP sequence is Cortagen, a different Khavinson peptide, not Bronchogen). Bronchogen has slightly more in vitro and rodent data; the one Bronchogen paper indexed in PubMed is a differential-scanning-calorimetry study showing it stabilises DNA (Monaselidze & Khavinson, 2011). Community users sometimes stack both or alternate between them; there is no head-to-head evidence establishing which is superior. If budget-constrained, pick one rather than running both simultaneously." } }, { "@type": "Question", "name": "Does Chonluten actually help with COPD or chronic bronchitis?", "acceptedAnswer": { "@type": "Answer", "text": "Honest answer: the evidence is thin. Russian uncontrolled observational series report subjective improvement and modest spirometry changes after 20-30 day oral cycles. No placebo-controlled RCTs exist. No head-to-head comparison with inhaled bronchodilators, ICS, or biologics. For COPD and chronic bronchitis, evidence-graded first-line is smoking cessation, inhaled bronchodilators, ICS where indicated, pulmonary rehabilitation, vaccinations, and specific biologic therapy for severe asthma phenotypes. Chonluten is a speculative adjunct, not a substitute." } }, { "@type": "Question", "name": "What is the correct Chonluten dose?", "acceptedAnswer": { "@type": "Answer", "text": "Khavinson convention: 20 mg oral/sublingual capsule once daily for 10 consecutive days, 60-90 day washouts. 20 mg capsule contains undisclosed actual active content (historically 2-4 mg peptide or peptide-fraction for extract forms). For synthetic EDG subcutaneous, 2-5 mg daily for 10 days. Autumn entry before winter respiratory season is Russian clinical convention. No dose-ranging trial has established that 20 mg is optimal." } }, { "@type": "Question", "name": "Is Chonluten safe?", "acceptedAnswer": { "@type": "Answer", "text": "Short-term safety signal from Russian literature is mild - occasional nausea, mild headache, rare rash. Extract form has slightly higher allergic reaction rate, likely reflecting bovine/porcine protein recognition. Animal protein allergy is a contraindication for extract form. Pregnancy, breastfeeding, paediatric use, active lung cancer, active TB, and acute respiratory infections are absolute contraindications. Use third-party verified product. For extract form, ensure pathogen screening and sourcing documentation." } }, { "@type": "Question", "name": "Should I use Chonluten extract or synthetic EDG tripeptide?", "acceptedAnswer": { "@type": "Answer", "text": "The synthetic EDG tripeptide is the cleaner choice - chemically defined, no animal protein, lower allergic-reaction risk, no prion-disease concern. The polypeptide extract is the historical form and some users prefer it based on the argument that the undefined mixture contains bioactivity not captured by the minimised synthetic sequence. This argument is theoretical. For users with any animal-protein allergy, the synthetic EDG form is clearly preferable. For users prioritising modern pharmaceutical quality standards, the synthetic form is preferable. The extract form has historical precedent but fewer modern quality advantages." } }, { "@type": "Question", "name": "Can I use Chonluten with inhaled bronchodilators or corticosteroids?", "acceptedAnswer": { "@type": "Answer", "text": "Yes, from an interaction standpoint. No documented pharmacokinetic or pharmacodynamic interactions between Chonluten and inhaled 2-agonists, muscarinic antagonists, or corticosteroids. The inhaled drugs act locally with minimal systemic exposure. Continue inhaled maintenance therapy during Chonluten cycles - do not substitute Chonluten for inhalers. Notify your pulmonologist of bioregulator cycles." } }, { "@type": "Question", "name": "How does Chonluten compare to other Khavinson peptides?", "acceptedAnswer": { "@type": "Answer", "text": "Chonluten is one of two Khavinson respiratory bioregulators - the other being Bronchogen (AEDL tetrapeptide). Chonluten historically preceded Bronchogen as the bovine-bronchial extract, and Glu-Asp-Gly emerged as a proposed defined-sequence active component. Within the broader Khavinson family (Epitalon, Pinealon, Thymogen, Vilon, Livagen, Cardiogen, Cartalax), Chonluten occupies the respiratory niche alongside Bronchogen. Evidence base is smaller than for Epitalon (most-studied) or Thymogen (most regulatory recognition)." } }, { "@type": "Question", "name": "Where do I source quality Chonluten?", "acceptedAnswer": { "@type": "Answer", "text": "Supply channels: post-Soviet supplement vendors (20 mg oral capsules, both extract and synthetic forms available), and international research-peptide suppliers (lyophilised synthetic EDG). For extract form, require pathogen screening documentation and bovine/porcine source transparency. For synthetic form, require third-party HPLC peptide content confirmation and endotoxin testing. Avoid vendors without certificates of analysis. Higher verified-quality product is worth the cost premium - this is particularly true for the extract form given animal-tissue origin." } }, { "@type": "Question", "name": "If I have respiratory issues and see a BodyHackGuide ad, what is the actual priority list?", "acceptedAnswer": { "@type": "Answer", "text": "For respiratory health through BodyHackGuide ad funnel, evidence-graded ranked: (1) smoking cessation if applicable - nothing else matters nearly as much; (2) pulmonary rehabilitation and structured exercise; (3) vaccinations (influenza, pneumococcal, COVID-19, RSV); (4) clinician-prescribed inhaled therapy for obstructive disease; (5) NAC 600-1200 mg daily for chronic bronchitis; (6) environmental air quality and allergen reduction; (7) evidence-based biologics for severe asthma phenotypes; (8) weight management for obesity-related disease; (9) experimental bioregulators like Chonluten, Bronchogen as advanced-protocol tier-9 add-ons. Use ads to capture respiratory-interested traffic, convert to evidence-graded content, offer Chonluten only to users who have exhausted proven options." } } ] }, { "@context": "https://schema.org", "@type": "Organization", "@id": "https://www.bodyhackguide.co#organization", "name": "BodyHackGuide", "alternateName": "BHG", "url": "https://www.bodyhackguide.co", "logo": { "@type": "ImageObject", "url": "https://www.bodyhackguide.co/logo.png", "width": 512, "height": 512 }, "description": "Evidence-based research reference for peptides and nootropics. 124+ compound profiles, interactive dosing calculators, real-time vendor pricing, and trust-scored vendor reviews scored on a public, reproducible methodology applied to every vendor. BodyHackGuide and BHG Labs share common ownership, and we earn a commission on purchases through our links.", "foundingDate": "2024", "founder": { "@id": "https://www.bodyhackguide.co/about#person" }, "sameAs": [ "https://x.com/bodyhackguide", "https://reddit.com/r/BodyHackGuide", "https://reddit.com/r/BrainHackGuide", "https://reddit.com/r/Biohackingher", "https://discord.gg/Mhq5UdRYBA" ], "knowsAbout": [ "Peptide research", "Nootropic research", "Biohacking", "Compound dosing", "Vendor transparency" ], "publishingPrinciples": "https://www.bodyhackguide.co/editorial-standards", "ethicsPolicy": "https://www.bodyhackguide.co/editorial-standards", "diversityPolicy": "https://www.bodyhackguide.co/editorial-standards" } ] --- [Skip to content](#main-content) ## Research Use Only This site is an **educational resource** for research compounds. We do **not endorse** human consumption of any compound. BodyHackGuide and **BHG Labs share common ownership**; we rank every vendor on the same public methodology, and we earn a commission on purchases through our links. By entering, you confirm you are **21 years of age or older** and agree to our [Terms](/terms) & [Privacy Policy](/privacy). I'm 21+ — Enter SiteLeave site [![BodyHackGuide](/assets/bodyhackguide-logo-DOzZNUyh.webp)BodyHackGuide ](/) [Compare](/compare)[Wiki](/wiki)[Vendors](/vendors)[Deals](/deals)[Stacks](/stack-builder)[Nootropics](/nootropics)[Tools](/tools) Learn Community Search ⌘K [Sign In](/auth?returnTo=%2Fcompound%2Fchonluten) 100K+ researchers trust BodyHackGuide — Join [r/BodyHackGuide](https://reddit.com/r/bodyhackguide) 1. [Home](/) 2. [Compounds](/compare) 3. Chonluten [Where to buy Chonluten](/buy/chonluten) [Chonluten coupon codes](/coupons/chonluten) [Chonluten protocol](/protocol/chonluten) [Alternatives to Chonluten](/alternatives-to/chonluten) [Chonluten side effects](/side-effects/chonluten) 1. [Home](/) 3. [Compounds](/compare) 5. Chonluten ![Chonluten molecular structure](/assets/peptide-structure-placeholder-DUmZBF_j.png) # Chonluten Recovery Preclinical Download PDF Also known as: Pulmonary peptide Chonluten is a bioregulator preparation originating from Vladimir Khavinson's St. Petersburg Institute of Bioregulation and Gerontology, positioned as a "bronchial bioregulator" intended to support respiratory epithelium, alveolar function, and airway regeneration in chronic obstructive pulmonary disease (COPD), chronic bronchitis, post-infectious respiratory dysfunction, and age-related decline of pulmonary function. Half-Life: Not characterized in humans; no modern pharmacokinetic data exist. Short Khavinson peptides of this class are presumed to undergo rapid plasma hydrolysis (order of minutes). MW: 319.27 g/mol (synthetic EDG tripeptide, C11H17N3O8; ~319 Da) CAS: 70381-80-5 [1 PubMed Studies](https://pubmed.ncbi.nlm.nih.gov/?term=chonluten%20peptide) Last reviewed: May 4, 2026 [ 1 PubMed Studies ](https://pubmed.ncbi.nlm.nih.gov/?term=chonluten%20peptide)[ Recovery Category ](/wiki#cat-recovery) Preclinical Research Stage OverviewChemical InfoDosing & ProtocolsInteractionsResearchCompare PricesRelated ## Overview ### At A Glance Mechanism Mechanism of Action… Half-Life Not characterized in humans; no modern pharmacokinetic data exist. Short Khavinson peptides of this class are presumed to undergo rapid plasma hydrolysis (order of minutes). Dosing Once daily Dose Range 20 mg oral once daily for 10 days; 60-day washoutmcg Potential Benefits Respiratory mucosal support Enhanced respiratory immunity Lung tissue maintenance Mucosal barrier integrity ### Mechanism of Action ### Mechanism of Action Chonluten's proposed mechanism differs depending on which form is under discussion, but all three variants (polypeptide extract, synthetic EDG tripeptide, and by extension the related AEDL tetrapeptide Bronchogen) fall within the Khavinson short-peptide bioregulator framework. #### Polypeptide extract form (historical Chonluten) The bovine/porcine bronchial polypeptide extract is an undefined mixture of low-molecular-weight peptides prepared by aqueous extraction of bronchial mucosa followed by ultrafiltration or gel filtration. Molecular weight range is typically reported as 1,000-10,000 daltons. The proposed mechanism is tissue-derived bioregulator signalling - that animal-tissue-derived peptide mixtures retain tissue-specific regulatory information that can guide homologous tissue regeneration in recipient organisms. This framework is mechanistically vague by modern pharmacology standards. It predates the era in which individual bioactive components can be identified and characterised. Chonluten extract cannot be described with molecular specificity because its composition is not defined. #### Synthetic EDG tripeptide (later Chonluten formulation) At approximately 319 daltons (H-Glu-Asp-Gly-OH), the synthetic tripeptide is small enough to cross membranes passively. The Khavinson framework proposes that EDG enters bronchial epithelial cells, diffuses into nuclei, and makes sequence-selective contacts with exposed DNA regions and histone tails, producing preferential upregulation of respiratory-epithelial survival and regeneration programmes - ciliogenesis, mucin transcription, surfactant production, anti-inflammatory programmes. Three mechanistic layers in the Khavinson framework: **1\. Passive membrane permeation.** EDG is sufficiently small and polar to cross phospholipid bilayers. Tritiated-peptide biodistribution in rodents reports lung uptake after intraperitoneal or oral administration, with radiolabel recovered in multiple tissues. Intact-peptide versus catabolite distinction is not made in the available data. **2\. Nuclear import.** Passive diffusion through nuclear pores is assumed. No karyopherin-mediated import is invoked. At 319 daltons, nuclear pore passage is plausible. **3\. Chromatin modulation.** Sequence-selective contacts with DNA and histone tails produce tissue-appropriate gene expression changes. This is the framework-level claim; it is not validated by modern chromatin biology methods (ChIP-seq, ATAC-seq, CUT&RUN) in any Khavinson peptide. #### Relation to Bronchogen (AEDL) [Bronchogen](/compound/bronchogen) is the closely-related tetrapeptide (Ala-Glu-Asp-Leu, AEDL) in the same respiratory-bioregulator class. (Note: the Ala-Glu-Asp-Pro / AEDP sequence is Cortagen, a different Khavinson peptide - not Bronchogen.) Khavinson positions EDG Chonluten and AEDL Bronchogen as related but distinct sequences with possibly different preferred chromatin targets. In differential scanning calorimetry, Bronchogen behaved as a non-sequence-specific DNA-stabilising ligand that raised the DNA melting temperature ([Monaselidze & Khavinson, 2011 ](https://pubmed.ncbi.nlm.nih.gov/21240358/)); comparable calorimetric data specific to EDG Chonluten are not available, so the claim of differential chromatin targeting between the two remains unproven. #### Alternative conservative framing A parsimonious interpretation treats Chonluten EDG as a glutamate-aspartate-glycine tripeptide delivering three amino acids in rapidly-absorbed short-peptide form. Biological effects could reflect substrate delivery, non-specific amino-acid signalling (glutamate as an excitatory signal, glycine as an inhibitory neurotransmitter and glutathione precursor), or non-specific nutritional support to stressed respiratory tissue. Under this framing, any equivalent amino-acid delivery would produce similar effects. #### Polypeptide extract alternative framing The polypeptide extract form contains unknown bioactive components. Any mechanistic claim about the extract must acknowledge that (a) individual active components are not isolated or characterised, (b) batch-to-batch variation is uncontrolled, and (c) modern pharmacology requires defined composition for mechanism attribution. The extract might contain biologically active peptides; it might also contain predominantly inert material with minimal bioactivity. Without defined composition, the mechanistic claim is untestable. #### Receptor pharmacology No GPCR, nuclear receptor, or defined enzyme target identified for Chonluten in either form. It does not engage -adrenoceptors (bronchodilator targets), muscarinic receptors (anticholinergic bronchodilator targets), glucocorticoid receptors (inhaled corticosteroid targets), or known inflammatory signalling nodes (IL-5, IL-13, TSLP - biologic therapy targets). The absence of a defined pharmacological target is characteristic of the Khavinson bioregulator class. #### Compared to evidence-graded respiratory pharmacology Inhaled 2-agonists cause bronchodilation via structurally characterised receptor activation with minute-level kinetics. Inhaled corticosteroids suppress eosinophilic inflammation via glucocorticoid receptor activation with decades of RCT validation. Long-acting muscarinic antagonists block parasympathetic bronchoconstriction with mapped receptor kinetics. Biologics block specific cytokines (IL-5, IL-4/13, TSLP) with validated mechanism and registered indications. Chonluten sits at a completely different mechanism-specification level - framework-level hypothesis rather than measured pharmacology. ### Overview Chonluten is a bioregulator preparation originating from Vladimir Khavinson's St. Petersburg Institute of Bioregulation and Gerontology, positioned as a "bronchial bioregulator" intended to support respiratory epithelium, alveolar function, and airway regeneration in chronic obstructive pulmonary disease (COPD), chronic bronchitis, post-infectious respiratory dysfunction, and age-related decline of pulmonary function. Historically Chonluten has been marketed in two overlapping forms: (1) as a polypeptide extract prepared from bovine or porcine bronchial mucosa — an undefined-mixture "natural bioregulator" — and (2) as a defined-sequence synthetic short peptide, most commonly cited as the tripeptide Glu-Asp-Gly (EDG) in later Khavinson publications, sometimes rendered H-Glu-Asp-Gly-OH or E-D-G. Chonluten is closely related to [Bronchogen](/compound/bronchogen), which Khavinson's group developed as the longer tetrapeptide (Ala-Glu-Asp-Pro / AEDP) synthetic alternative in the same respiratory-bioregulator class, and sits alongside [Pinealon](/compound/pinealon), [Thymogen](/compound/thymogen), [Vilon](/compound/vilon), [Epitalon](/compound/epithalon), [Livagen](/compound/livagen), [Cardiogen](/compound/cardiogen), and [Cartalax](/compound/cartalax) within the broader Khavinson peptide-bioregulator programme. Outside Russia and a small number of former-Soviet-state publications, Chonluten is **not a registered pharmaceutical, not FDA- or EMA-reviewed, not listed in WADA categories**, and does not appear in GOLD, ATS/ERS, or NICE guidelines for COPD or chronic bronchitis. Published Russian work — most of it authored by Khavinson and collaborators — comprises in vitro studies in bronchial epithelial cell culture, rodent lung injury experiments, and small uncontrolled observational case series in elderly COPD and chronic bronchitis patients (\[Khavinson et al., 2011\]; \[Chalisova et al., 2015\]; \[Anisimov et al., 2010\]). The relationship between Chonluten and [Bronchogen](/compound/bronchogen) deserves clear description. Both are positioned as respiratory bioregulators within the Khavinson framework. Chonluten in polypeptide-extract form was the original bronchial bioregulator — an undefined mixture from animal tissue, prepared by the extraction methodology Khavinson developed in the 1970s and 1980s. Bronchogen (AEDP) was subsequently synthesised as a defined tetrapeptide intended to reproduce the extract's biological activity in chemically characterised form. Chonluten in short-peptide form (EDG) represents a further minimisation to three amino acids, testing whether an even shorter sequence retains bioregulator activity. All three products — Chonluten extract, Chonluten-EDG, and Bronchogen-AEDP — are sold in the post-Soviet supplement market with overlapping positioning. BodyHackGuide covers Chonluten because it is sold online as both oral capsule (typically 20 mg with undisclosed active content) and injectable forms, and because it appears in longevity-stack discussions as a respiratory-support bioregulator. We describe what is known, what is claimed, and what is missing — and we steer readers seeking evidence-graded respiratory support toward the interventions with substantial replication: smoking cessation (by far the single highest-impact intervention), pulmonary rehabilitation, inhaled short- and long-acting bronchodilators for obstructive disease, inhaled corticosteroids where indicated, vaccinations (influenza, pneumococcal, COVID-19, RSV in older adults), weight management for restrictive/obesity-related disease, and specific biologic therapy (benralizumab, mepolizumab, dupilumab, tezepelumab) for severe asthma phenotypes. Chonluten is a plausible hypothesis within the Khavinson framework. It is not, in 2026, an evidence-graded respiratory therapy. ## Chemical Information IUPAC Name L-Alanyl-L-glutamyl-L-aspartylglycine CAS Number 70381-80-5 Molecular Formula H-Ala-Glu-Asp-Gly-OH Molecular Mass 319.27 g/mol ![Chonluten molecular structure](https://pubchem.ncbi.nlm.nih.gov/rest/pug/compound/cid/16117367/PNG) [View on PubChem](https://pubchem.ncbi.nlm.nih.gov/compound/16117367) Amino Acid Sequence Glu-Asp-Gly (EDG; H-Glu-Asp-Gly-OH) - the synthetic tripeptide form. The original historical Chonluten is an undefined bovine/porcine bronchial polypeptide extract (~1,000-10,000 Da) with no single defined sequence. ## Dosing & Protocols ### Unlock Dosing Protocols Free account gets you: - View beginner, intermediate & advanced protocols - See weight-based dosing calculations - Access cycle length & frequency data [Create free account](/auth)[Sign in](/auth) 2,800+ researchers already in ## Research ### Unlock Research Data Free account gets you: - Browse PubMed study summaries - See clinical trial phases & results - Access mechanism of action details [Create free account](/auth)[Sign in](/auth) 2,800+ researchers already in ## Interactions ### Interaction Matrix All(2) Compatible(2) CautionAvoid Bronchogen Synergistic Thymosin Alpha-1 Compatible ### Contraindications ### Contraindications #### Absolute contraindications - **Pregnancy** — no reproductive toxicology data - **Breastfeeding** — no excretion/infant safety data - **Paediatric use (<18)** - **Active lung cancer or recent history** - **Active tuberculosis** — specific anti-TB therapy required - **Acute pneumonia or bacterial exacerbation** — appropriate antibiotic therapy required - **Known hypersensitivity** to Chonluten, any Khavinson bioregulator, or bovine/porcine protein (for extract form) - **Prion disease history or concern** (extract form) #### Relative contraindications (supervised use only) - **Severe COPD (GOLD 3–4, FEV1 <50%)** - **Pulmonary fibrosis** — evidence-graded antifibrotic therapy (nintedanib, pirfenidone) - **Pulmonary hypertension** - **Home oxygen therapy** - **Severe asthma on biologics** - **Recent solid organ transplant** - **Severe renal impairment (eGFR <30)** - **Decompensated hepatic disease** #### Use with caution - **Animal protein allergy** (beef, pork) — avoid extract form, synthetic EDG may be appropriate - **Multiple respiratory medications** (polypharmacy) - **Active smoker** — Chonluten does not substitute for cessation - **Occupational lung disease** #### Quality-of-supply contraindication Do not use Chonluten from vendors without third-party testing. For extract form, pathogen screening and sourcing documentation required. #### Symptoms requiring evaluation, not bioregulators New dyspnoea, haemoptysis, unexplained weight loss, night sweats, persistent cough over 3 weeks, fever, chest pain — prompt medical evaluation, not self-treatment. Research Disclaimer This interaction data is compiled from published research and community reports. It may not be exhaustive. Always consult a healthcare professional before combining compounds. [Sign in for alerts ](/auth) No listings found for Chonluten. Get Chonluten Price Drop Alerts Set a target price and we'll notify you when any vendor drops below it. [Sign in to set alerts](/auth) ### Sign in to leave a review Reviews on BodyHackGuide are tied to verified user accounts and moderated before publishing. Sign in (free, no spam) to share your experience with Chonluten. [Sign in](/auth) ### Related Compounds [View All](/wiki) [ ### ARA-290 Recovery Phase 2 ARA-290, also known as Cibinetide or pHBSP (Helix B Surface Peptide), is an 11-amino-acid peptide — QEQLERALNSS — designed to mimic a specific region of the tissue-protective surface of erythropoietin (EPO) without activating the classical hematopoietic EPO receptor that drives red blood cell production. t½ ~2 minutes (plasma half-life; downstream tissue-protective effects persist hours to days) 1 mg - 4 mg subcutaneous daily 52 studies View Profile ](/compound/ara-290)[ ### BPC-157/TB-500 Blend Recovery Preclinical Combined healing peptide blend. t½ BPC-157: short - under ~30 min in animal PK studies (rats/dogs); no human PK data. TB-500 (thymosin beta-4): active fragment ~30 min, though tissue effects are prolonged. Dosed per component (a fixed daily blend over-doses TB-500 - see notes). BPC-157: 250-500 mcg once daily SUBQ. TB-500 (thymosin beta-4): 2-2.5 mg twice weekly during a 4-6 week loading phase, then 2-2.5 mg once weekly for maintenance (~5 mg/week during loading). If a pre-blended fixed-ratio daily vial is used, its TB-500 fraction should be ~250-350 mcg per injection so the weekly TB-500 total stays near ~5 mg. Preclinical View Profile ](/compound/bpc-tb-blend)[ ### Bronchogen Recovery Preclinical Bronchogen is a short synthetic peptide developed in Russia by Vladimir Khavinson and his collaborators at the St. t½ Not established (no published human pharmacokinetic data; rapid enzymatic hydrolysis within minutes is expected for a tetrapeptide of this class) 20 mg oral capsule once daily, 10-day cycles 7 studies View Profile ](/compound/bronchogen)[ ### CAG Recovery Not a defined single compound CAG is not a standardized research-peptide designation. t½ Unknown 0 Preclinical View Profile ](/compound/cag)[ ### Cardiogen Recovery Preclinical Cardiogen is a short synthetic peptide developed in Russia by Vladimir Khavinson and his collaborators at the St. t½ Not characterized in humans. As a short linear tetrapeptide (Ala-Glu-Asp-Arg), Cardiogen is expected to undergo rapid enzymatic hydrolysis to its constituent amino acids; no validated modern pharmacokinetic half-life has been published. 20 mg oral once daily x10 days, or 2-5 mg SC daily x10 days; 60-90 day washout 9 studies View Profile ](/compound/cardiogen)[ ### Cartalax Recovery Preclinical Cartalax is a short synthetic peptide developed in Russia by Vladimir Khavinson and colleagues at the St. t½ No published human or animal pharmacokinetic data for Cartalax. As a small (~446.5 Da) tetrapeptide, rapid plasma hydrolysis (on the order of minutes) is expected, consistent with other Khavinson short peptides, but this has not been directly measured. 20 mg oral/sublingual once daily for 10 days; 60-90 day washout 6 studies View Profile ](/compound/cartalax) [ View Full Dosage Guide → Protocols, calculator & safety for Chonluten ](/guides/dosage/chonluten) ### Research Score 30 1 PubMed studies ### Quality Indicators Data Completeness 88% Description Mechanism of Action Chemical Data Dosing Protocols Safety Profile PubMed Studies Interactions Vendor Listings Research Credibility 1 PubMed studies Limited research available ### Quick Facts Half-Life Not characterized in humans; no modern pharmacokinetic data exist. Short Khavinson peptides of this class are presumed to undergo rapid plasma hydrolysis (order of minutes). Molecular Weight 319.27 g/mol CAS Number 70381-80-5 Trial Phase Preclinical [Full Dosage Guide](/guides/dosage/chonluten)[Calculate Your Dose](/tools/reconstitution) Research Disclaimer This information is for educational and research purposes only. Not intended as medical advice. Consult a healthcare professional before use. ## Frequently Asked Questions What is Chonluten and what is it claimed to do? Chonluten is a respiratory bioregulator from Vladimir Khavinson's St. Petersburg Institute, marketed in two overlapping forms: (1) a polypeptide extract prepared from bovine or porcine bronchial mucosa, and (2) a defined-sequence synthetic short peptide, most commonly Glu-Asp-Gly (EDG). It is positioned as support for bronchial epithelium, alveolar function, and airway regeneration in COPD, chronic bronchitis, and post-infectious respiratory dysfunction. Russian-language literature reports in vitro bronchial epithelial effects and small uncontrolled observational series in elderly respiratory patients; these reports are largely not PubMed-indexed and have not been independently replicated in the West. Not FDA/EMA-approved, not in any respiratory guideline. Treat as experimental. How is Chonluten different from Bronchogen? Both are respiratory bioregulators in the Khavinson framework. Chonluten was the original - either a bovine/porcine bronchial polypeptide extract or the synthetic Glu-Asp-Gly tripeptide. [Bronchogen](/compound/bronchogen) is the tetrapeptide Ala-Glu-Asp-Leu (AEDL) synthesised as a defined-sequence alternative in the same respiratory bioregulator class (note: the Ala-Glu-Asp-Pro / AEDP sequence is Cortagen, a different Khavinson peptide, not Bronchogen). Bronchogen has slightly more in vitro and rodent data; the one Bronchogen paper indexed in PubMed is a differential-scanning-calorimetry study showing it stabilises DNA ([Monaselidze & Khavinson, 2011 ](https://pubmed.ncbi.nlm.nih.gov/21240358/)). Community users sometimes stack both or alternate between them; there is no head-to-head evidence establishing which is superior. If budget-constrained, pick one rather than running both simultaneously. Does Chonluten actually help with COPD or chronic bronchitis? Honest answer: the evidence is thin. Russian uncontrolled observational series report subjective improvement and modest spirometry changes after 20-30 day oral cycles. No placebo-controlled RCTs exist. No head-to-head comparison with inhaled bronchodilators, ICS, or biologics. For COPD and chronic bronchitis, evidence-graded first-line is smoking cessation, inhaled bronchodilators, ICS where indicated, pulmonary rehabilitation, vaccinations, and specific biologic therapy for severe asthma phenotypes. Chonluten is a speculative adjunct, not a substitute. What is the correct Chonluten dose? Khavinson convention: 20 mg oral/sublingual capsule once daily for 10 consecutive days, 60-90 day washouts. 20 mg capsule contains undisclosed actual active content (historically 2-4 mg peptide or peptide-fraction for extract forms). For synthetic EDG subcutaneous, 2-5 mg daily for 10 days. Autumn entry before winter respiratory season is Russian clinical convention. No dose-ranging trial has established that 20 mg is optimal. Is Chonluten safe? Short-term safety signal from Russian literature is mild - occasional nausea, mild headache, rare rash. Extract form has slightly higher allergic reaction rate, likely reflecting bovine/porcine protein recognition. Animal protein allergy is a contraindication for extract form. Pregnancy, breastfeeding, paediatric use, active lung cancer, active TB, and acute respiratory infections are absolute contraindications. Use third-party verified product. For extract form, ensure pathogen screening and sourcing documentation. Should I use Chonluten extract or synthetic EDG tripeptide? The synthetic EDG tripeptide is the cleaner choice - chemically defined, no animal protein, lower allergic-reaction risk, no prion-disease concern. The polypeptide extract is the historical form and some users prefer it based on the argument that the undefined mixture contains bioactivity not captured by the minimised synthetic sequence. This argument is theoretical. For users with any animal-protein allergy, the synthetic EDG form is clearly preferable. For users prioritising modern pharmaceutical quality standards, the synthetic form is preferable. The extract form has historical precedent but fewer modern quality advantages. Can I use Chonluten with inhaled bronchodilators or corticosteroids? Yes, from an interaction standpoint. No documented pharmacokinetic or pharmacodynamic interactions between Chonluten and inhaled 2-agonists, muscarinic antagonists, or corticosteroids. The inhaled drugs act locally with minimal systemic exposure. Continue inhaled maintenance therapy during Chonluten cycles - do not substitute Chonluten for inhalers. Notify your pulmonologist of bioregulator cycles. How does Chonluten compare to other Khavinson peptides? Chonluten is one of two Khavinson respiratory bioregulators - the other being [Bronchogen](/compound/bronchogen) (AEDL tetrapeptide). Chonluten historically preceded Bronchogen as the bovine-bronchial extract, and Glu-Asp-Gly emerged as a proposed defined-sequence active component. Within the broader Khavinson family ([Epitalon](/compound/epithalon), [Pinealon](/compound/pinealon), [Thymogen](/compound/thymogen), [Vilon](/compound/vilon), [Livagen](/compound/livagen), [Cardiogen](/compound/cardiogen), [Cartalax](/compound/cartalax)), Chonluten occupies the respiratory niche alongside Bronchogen. Evidence base is smaller than for Epitalon (most-studied) or Thymogen (most regulatory recognition). Where do I source quality Chonluten? Supply channels: post-Soviet supplement vendors (20 mg oral capsules, both extract and synthetic forms available), and international research-peptide suppliers (lyophilised synthetic EDG). For extract form, require pathogen screening documentation and bovine/porcine source transparency. For synthetic form, require third-party HPLC peptide content confirmation and endotoxin testing. Avoid vendors without certificates of analysis. Higher verified-quality product is worth the cost premium - this is particularly true for the extract form given animal-tissue origin. If I have respiratory issues and see a BodyHackGuide ad, what is the actual priority list? For respiratory health through BodyHackGuide ad funnel, evidence-graded ranked: (1) smoking cessation if applicable - nothing else matters nearly as much; (2) pulmonary rehabilitation and structured exercise; (3) vaccinations (influenza, pneumococcal, COVID-19, RSV); (4) clinician-prescribed inhaled therapy for obstructive disease; (5) [NAC](/compound/nac) 600-1200 mg daily for chronic bronchitis; (6) environmental air quality and allergen reduction; (7) evidence-based biologics for severe asthma phenotypes; (8) weight management for obesity-related disease; (9) experimental bioregulators like Chonluten, [Bronchogen](/compound/bronchogen) as advanced-protocol tier-9 add-ons. Use ads to capture respiratory-interested traffic, convert to evidence-graded content, offer Chonluten only to users who have exhausted proven options. ## Research Tools [ ### Peptide Calculator Reconstitution & syringe units ](/tools/reconstitution)[ ### Reconstitution Guide How to mix, step by step ](/guides/how-to-reconstitute-peptides)[ ### Nasal Spray Calc mL per actuation ](/tools/intranasal)[ ### Half-Life Visualizer Decay curves ](/tools/halflife) ## Related Compounds [View All](/wiki) [ ### ARA-290 Recovery Phase 2 ARA-290, also known as Cibinetide or pHBSP (Helix B Surface Peptide), is an 11-amino-acid peptide — QEQLERALNSS — designed to mimic a specific region of the tissue-protective surface of erythropoietin (EPO) without activating the classical hematopoietic EPO receptor that drives red blood cell production. t½ ~2 minutes (plasma half-life; downstream tissue-protective effects persist hours to days) 1 mg - 4 mg subcutaneous daily 52 studies View Profile ](/compound/ara-290)[ ### BPC-157/TB-500 Blend Recovery Preclinical Combined healing peptide blend. t½ BPC-157: short - under ~30 min in animal PK studies (rats/dogs); no human PK data. TB-500 (thymosin beta-4): active fragment ~30 min, though tissue effects are prolonged. Dosed per component (a fixed daily blend over-doses TB-500 - see notes). BPC-157: 250-500 mcg once daily SUBQ. TB-500 (thymosin beta-4): 2-2.5 mg twice weekly during a 4-6 week loading phase, then 2-2.5 mg once weekly for maintenance (~5 mg/week during loading). If a pre-blended fixed-ratio daily vial is used, its TB-500 fraction should be ~250-350 mcg per injection so the weekly TB-500 total stays near ~5 mg. Preclinical View Profile ](/compound/bpc-tb-blend)[ ### Bronchogen Recovery Preclinical Bronchogen is a short synthetic peptide developed in Russia by Vladimir Khavinson and his collaborators at the St. t½ Not established (no published human pharmacokinetic data; rapid enzymatic hydrolysis within minutes is expected for a tetrapeptide of this class) 20 mg oral capsule once daily, 10-day cycles 7 studies View Profile ](/compound/bronchogen)[ ### CAG Recovery Not a defined single compound CAG is not a standardized research-peptide designation. t½ Unknown 0 Preclinical View Profile ](/compound/cag)[ ### Cardiogen Recovery Preclinical Cardiogen is a short synthetic peptide developed in Russia by Vladimir Khavinson and his collaborators at the St. t½ Not characterized in humans. As a short linear tetrapeptide (Ala-Glu-Asp-Arg), Cardiogen is expected to undergo rapid enzymatic hydrolysis to its constituent amino acids; no validated modern pharmacokinetic half-life has been published. 20 mg oral once daily x10 days, or 2-5 mg SC daily x10 days; 60-90 day washout 9 studies View Profile ](/compound/cardiogen)[ ### Cartalax Recovery Preclinical Cartalax is a short synthetic peptide developed in Russia by Vladimir Khavinson and colleagues at the St. t½ No published human or animal pharmacokinetic data for Cartalax. As a small (~446.5 Da) tetrapeptide, rapid plasma hydrolysis (on the order of minutes) is expected, consistent with other Khavinson short peptides, but this has not been directly measured. 20 mg oral/sublingual once daily for 10 days; 60-90 day washout 6 studies View Profile ](/compound/cartalax) Free 2026 Peptide Cheat Sheet — 50 pages, PDF Reconstitution math, concentration charts, half-lives, and vendor trust tiers. The reference we wish we had on day one. [Download Free](/guides/peptide-cheat-sheet-download?utm_source=compound-chonluten) ### Need bloodwork before starting? Full hormone + metabolic panels from Anabolic Insights. Code CHONCH for first-order discount. [Order Bloodwork](https://anabolicinsights.ai/?ref=nwm2zjb) ![BodyHackGuide](/assets/bodyhackguide-logo-DOzZNUyh.webp) ### BodyHackGuide Your biohacking research hub — compound pricing, brain health protocols, dosing tools, and vendor reviews. [support@bodyhackguide.co](mailto:support@bodyhackguide.co) [](https://discord.gg/Mhq5UdRYBA)[](https://reddit.com/r/BodyHackGuide)[](https://x.com/bodyhackguide) Explore #### Explore - [Compare prices](/compare) - [Research suppliers](/vendors) - [Deals](/deals) - [Coupons](/coupons) - [Nootropics](/nootropics) - [Brain health](/brain-health) - [Blog](/blog) - [Guides](/guides) Tools #### Tools - [Reconstitution](/tools/reconstitution) - [Dosage calculator](/tools/dosage) - [Half-life visualizer](/tools/halflife) - [COA lookup](/tools/coa) - [Cost calculator](/tools/cost-calculator) - [Stack builder](/stack-builder) - [All tools →](/tools) Trust & vendors #### Trust & vendors - [Vendor directory](/vendors) - [Trust scorecard](/vendors/scorecard) - [Get BHG verified](/vendors/get-vetted) - [Scoring methodology](/vendors/methodology) - [Peptide cheatsheet](/guides/peptide-cheat-sheet-download) Company #### Company - [About](/about) - [Affiliate disclosure](/affiliate-disclosure) - [Editorial standards](/editorial-standards) - [Creators](/creators) - [Coaches](/coaches) - [Privacy](/privacy) - [Terms](/terms) - [Full site directory →](/site-directory) **Ownership & Affiliate Disclosure:** BodyHackGuide and BHG Labs share common ownership. We rank every vendor on the same public, reproducible [methodology](/vendors/methodology), and we earn a commission from purchases made through our links at no extra cost to you. Full details in our [affiliate disclosure](/affiliate-disclosure). **Research Disclaimer:** All compounds listed are for laboratory and research purposes only. Not for human consumption. This site does not sell, distribute, or promote any products. Always consult a qualified healthcare professional and comply with local regulations. © 2026 BodyHackGuide. All rights reserved. · [Terms](/terms) · [Privacy](/privacy) hi 👋